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Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases targeted for 
elimination. The only safe drug treatment with substantial curative activity against the filarial 
nematodes responsible for LF (Brugia malayi, Wuchereria bancrofti) or onchocerciasis (Onchocerca 
volvulus) is doxycycline. The target of doxycycline is the essential endosymbiont, Wolbachia. Four to six 
weeks doxycycline therapy achieves >90% depletion of Wolbachia in worm tissues leading to blockade 
of embryogenesis, adult sterility and premature death 18–24 months post-treatment. Long treatment 
length and contraindications in children and pregnancy are obstacles to implementing doxycycline 
as a public health strategy. Here we determine, via preclinical infection models of Brugia malayi or 
Onchocerca ochengi that elevated exposures of orally-administered rifampicin can lead to Wolbachia 
depletions from filariae more rapidly than those achieved by doxycycline. Dose escalation of rifampicin 
achieves >90% Wolbachia depletion in time periods of 7 days in B. malayi and 14 days in O. ochengi. 
Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analysis, we conclude 
that clinically relevant dose elevations of rifampicin, which have recently been determined as safe in 
humans, could be administered as short courses to filariasis target populations with potential to reduce 
anti-Wolbachia curative therapy times to between one and two weeks.
Lymphatic Filariasis (LF) and onchocerciasis are vector-borne diseases that endure as public health problems 
despite the efforts of sustained elimination programmes1–3. LF remains wide-spread throughout the tropics, 
affecting 120 million individuals with 1.1 billion at risk of infection4. It is symptomatically characterised by lym-
phoedema, hydrocele and elephantiasis and is the second leading cause of global disability5. Onchocerciasis is 
endemic in much of Sub-Saharan Africa, as well as more limited foci in Brazil, Venezuela and The Yemen with 37 
million infected6, 7. Onchocerciasis is the cause of skin disease and, in its most severe presentation, a sclerosing 
ocular keratitis (river blindness) which affects 0.8 million individuals and is the second most prevalent cause 
of infection-related preventable blindness7–9. LF and onchocerciasis are both targeted for elimination as public 
health problems10, 11. The current strategy of elimination is mass drug administration (MDA) with anti-filarial 
1Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. 
2Research Foundation in Tropical Medicine and the Environment, Buea, Cameroon. 3Department of Microbiology 
and Parasitology, University of Buea, Buea, Cameroon. Correspondence and requests for materials should be 
addressed to M.J.T. (email: Mark.Taylor@lstmed.ac.uk)
Received: 4 October 2016
Accepted: 21 February 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 210  | DOI:10.1038/s41598-017-00322-5
drugs, which target the transmissive first-stage larvae (microfilariae; mf) produced by mating adult filariae2, 3, 12 
For LF, the standard treatment is once single annual treatment with diethylcarbamazine (DEC) and albendazole 
(ABZ) in Asia, South America and Polynesia13. Due to contraindications of DEC in areas of potential overlapping 
onchocerciasis distribution in Africa, DEC is contraindicated (due to risk of severe ocular adverse reactions)13, 
14 and ivermectin (IVM) is substituted in combination with ABZ15–18. IVM is also used as a monotherapy in 
once- or twice-annual MDA for the elimination of onchocerciasis19, 20. Because standard anti-filarial drugs given 
in these dosages and/or combinations have little macrofilaricidal activity, they have to be administered with high 
population coverage and repetitively over many years in order to break the transmission cycle of the long-lived, 
reproductively active adult filarial infections. This is predicted as at least five annual rounds for LF and fifteen 
annual rounds for onchocerciasis2, 3, 16, 17, 20, with the former a minimum timeframe to initiate transmission assess-
ment surveys.
MDA has undoubtedly both reduced the burden of onchocerciasis disease and achieved nationwide elimi-
nation outcomes for LF21–28 in certain country settings. In other countries, however, failures of the approach are 
manifest. ‘Hot-spot’ residual foci of infections persist despite sustained coverage due to emerging resistance or 
other factors29–32, in certain regions, poor adherence to treatment is recorded, in part due to incidence of severe 
neurological adverse reactions to Loa loa co-infections33, 34 in hard-to-reach areas, inadequate coverage is appar-
ent and certain country elimination programmes are yet to commence4, 7 In these scenarios, if LF and onchocerci-
asis elimination targets within ambitious 2030 United Nations Sustainable Development Goal (SDG) timeframes 
are to be achieved, there is an urgent need to implement alternative strategies. Affordable registered drugs, which 
have evidence of curative activity against filariae, and could be re-purposed to cure target populations within a 
test-and-treat delivery, are considered the most expeditious solution toward achieving elimination targets where 
deployed to mop up residual foci during the elimination ‘end-game’.
The antibiotic, doxycycline, has been shown to indirectly exert significant macrofilaricidal activity by targeting 
the filarial endosymbiotic bacteria Wolbachia34, 35. Through a series of clinical trials in LF36–41 and onchocerciasis 
patients42–45, sustained, >90% depletion of Wolbachia from filarial tissues consequently mediates inhibition of 
embryogenesis, infertility, clearance of mf from the blood or skin and ultimately death of the adult filariae in 
18–24 months35, 46. Effects of depleting Wolbachia within migratory mf have also been demonstrated to hinder 
development to the infectious larval stage in intermediate vectors47. Sustained amicrofilaraemia/amicrofilari-
dermia following a single course of doxycycline48, 49 leads to symptomatic relief and halts disease progression 
in onchocerciasis and interrupts transmission in both LF and onchocerciasis. Dose regimen reductions dur-
ing clinical studies and subsequent modelling of curative trial outcomes for onchocerciasis50 have defined that 
doxycycline achieves significant macrofilaricidal activity via >90% Wolbachia depletion in both LF48, 49, 51 and 
onchocerciasis42, 44, 52 after 4 to 6 weeks of daily administration, dependent on dose (100 or 200 mg) and the target 
organism (Wuchereria, Brugia or Onchocerca).
However, two major impediments remain for the implementation of an anti-Wolbachia therapeutic approach 
based on doxycycline. The long treatment duration of 4 weeks minimum imposes a logistical challenge and risk 
poor adherence, whereby shorter durations of doxycycline treatment, although achieving significant Wolbachia 
reductions and impacting on embryogenesis, fail to achieve significant curative outcomes53, 54. Secondly, doxycy-
cline is contraindicated in significant proportions of the population such as in pregnancy and children of 8 years 
of age or younger55.
In this work, a strategy for achieving the equivalent efficacy of long-course doxycycline treatment by using a 
high dose of rifampicin for 1–2 weeks is presented. For this, preclinical in vivo mouse models of Brugia malayi 
or Onchocerca ochengi adult worm infections56, are used to compare the activity of different orally administered 
dosages to establish a PK-PD relationship of rifampicin that is translatable to humans. Using these empirical 
rifampicin experiments and PK-PD analysis we provide preclinical evidence to justify phase II trials re-purposing 
high dose rifampicin to deliver curative outcomes in periods of between 1 to 2 weeks.
Results
Intrinsic anti-Wolbachia potency of rifampicin is superior to doxycycline. Table 1 shows in its first 
row, the in-vitro IC50 levels obtained for doxycycline and rifampicin in the Wolbachia infected C6/36 cell (C6/36 
wAlbB) assay57. Rifampicin exhibited an EC50 of 1.3 nM, which was approximately 16.2 fold more potent than that 
of doxycycline (EC50 = 22 nM), against Wolbachia. Both drugs resulted in killing ~90% of Wolbachia in compari-
son to vehicle control cell cultures at the end of the 7 day experiment.
Pharmacokinetics of rifampicin are superior to doxycycline. Figure 1 shows the pharmacokinetic 
profiles measured in SCID mice at days 1 and 7 for doxycycline or rifampicin at a dose of 25 mg/kg bid. Table 2 
Drug Doxycycline Rifampicin
Ratio 
(doxycycline/
rifampicin)
in-vitro 
IC50 (mg/
mL)
22 1.3 16.9
in-vivo IC50 
(µg/mL) 1059 65 16.3
Table 1. In-vitro and in-vivo IC50 values of doxycycline and rifampicin calculated based on the individual 
potency of each drug in the dose escalation studies in animals using PK-PD modelling.
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summarises the pharmacokinetic parameters of each drug. Rifampicin (CL/F = 0.11 L/hr/kg) exhibited ~10 fold 
higher exposure at the same dose than doxycycline (CL/F = 1.2 L/h/kg). Clearance values at day 1 and day 7 were 
not statistically different (Mann-Whitney test, n = 5 mice, P > 0.05) and as shown in Table 2 all pharmacokinet-
ics parameters of both drugs did not significantly change after chronic exposure in comparison to single dose 
administration.
Anti-Wolbachia activity of rifampicin is superior to doxycycline in adult filarial infection mod-
els. We compared the anti-Wolbachia activity of rifampicin (5 mg/kg qd, 15 mg/kg qd, 35 mg/kg qd or 25 mg/
kg bid) with doxycycline (25 mg/kg bid) in B. malayi and O. ochengi SCID mouse models (Fig. 2). The murine 
doxycycline dose had been previously defined as bioequivalent to clinical dosing with 100 mg/day58. Wolbachia 
rate-of-kill was examined by four day dosing of mice infected with adult-stage B. malayi followed by termina-
tion +24 h after last dose and retrieval of female adults for assessment of Wolbachia loads (Fig. 2a). Changes in 
Wolbachia post-dosing were calculated as a % reduction compared with the median level in the vehicle control 
Figure 1. Pharmacokinetic profiles. Systemic exposure to doxycycline (DOX) and rifampicin (RIF) in BALB/c 
SCID mice are shown as follows. (a) PK profile of DOX after single 25 mg/kg dose. (b) PK profile of DOX at day 
7 after 7 bi-daily 25 mg/kg doses. (c) PK profile of RIF after single 25 mg/kg dose. (d) PK profile of RIF at day 7 
after 7 bi-daily 25 mg/kg doses.
Drug Doxycycline Rifampicin
Duration Single 7 day Single 7 day
Dose (mg/kg) 25 mg/kg 25 mg/kg bid 25 mg/kg 25 mg/kg bid
CL/F (L/hr/kg) 1.9 1.4 0.11 0.128
V/F (L/kg) 7.0 8.2 1.45 1.551
AUC (mg.h/L) 
(0–8 h) 12.2 15.6 90.9 81.3
Table 2. Pharmacokinetic parameters of doxycycline and rifampicin and after single dose and chronic dose 
administration.
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group. Bioequivalent doxycycline mediated a 41.3% reduction in Wolbachia after +4 day exposures. In compari-
son, low dose rifampicin (5 mg/kg qd) mediated a significantly higher 66.3% reduction over the same time period 
Figure 2. Pharmacological Outputs: Anti-filarial, anti-Wolbachia pharmacological effects of doxycycline 
(DOX) and rifampicin (RIF) in vivo. immediate pharmacological effects of DOX and RIF on Brugia malayi 
female adult Wolbachia loads (a,b) or post-washout (c,d). Effects on B. malayi microfilariae (Bmmf) 
production (e). Effects on Onchocerca ochengi male adult Wolbachia loads post-washout (f,g). Box and whiskers 
represent min-max (n = 10–29; B. malayi Wolbachia, n = 4–25; Bmmf, n = 5–17 O. ochengi Wolbachia). Solid 
line = control median Wolbachia level, long dashed line = 90%, short dashed line = 99% depletion level. 
Significance indicated *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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(1 way ANOVA F = 7.561, P = 0.002, Dunnett’s multiple comparisons test P < 0.05 vs DOX; Fig. 2b) whilst high 
dose rifampicin (15 mg/kg qd) mediated a 76.0% median reduction (P < 0.01 vs DOX; Fig. 2b).
Elevations in oral rifampicin dose were undertaken to evaluate whether >90% threshold level Wolbachia 
depletions in female filarial tissues could be achieved in a time frame of seven days dosing. Six to seven week-old 
B. malayi timed infections were targeted with an additional washout period of five weeks to allow for contin-
ued depletion or recrudescence of the Wolbachia population to be evident, as previously reported59, 60) (Fig. 2c). 
Doxycycline, at human bioequivalent (100 mg/day) dose58, was administered for four or six weeks (the latter a 
clinical dose time frame proven to deliver >90% Wolbachia depletion in B. malayi39 to compare with the efficacy 
of increasing dosages of short-course rifampicin regimens. As expected for ‘slow-killing’ anti-Wolbachia macro-
filaricides, there were no significant changes in B. malayi worm burdens in either doxycycline or rifampicin dosed 
mouse groups compared with vehicle controls (Table 3).
Doxycycline mediated an 88.1% median reduction in Wolbachia after four week dosing and 99.76% median 
reduction after six week dosing. In comparison, low dose rifampicin (5 mg/kg qd x 7d) was sub-optimal and sta-
tistically inferior to doxycycline, with a 58.3% median reduction (Kruskal-Wallis test P < 0.0001, Dunn’s multiple 
comparisons test, P < 0.0001 vs +42d DOX; Fig. 2d). Elevation of rifampicin dose to 15 mg/kg qd, 35 mg/kg qd or 
25 mg/kg bid delivered 97.7%, 98.2% or 99.5% median Wolbachia reductions, respectively. These dose effects were 
statistically non-inferior to six-week doxycycline dosing. Rifampicin 25 mg/kg bid dosing for seven days displayed 
significantly superior anti-Wolbachia activity to four-week doxycycline (P < 0.0001) and 15 mg/kg qd or 25 mg/kg 
bid rifampicin were superior to 5 mg/kg rifampicin after seven day dosing (P < 0.05 and P < 0.0001, respectively; 
Fig. 2d). Examining the impact of anti-Wolbachia efficacy on mf release, four or six-week doxycycline mediated 
a complete absence of viable mf within the peritoneal infection site (5/5 or 4/4 mice mf negative vs 2/25 mf neg-
ative vehicle; Kruskal-Wallis test P < 0.0001, Dunn’s multiple comparisons test, P < 0.01 or P < 0.05 vs vehicle; 
Fig. 2f). Low-dose rifampicin (5 mg/kg qd) did not significantly affect the peritoneal B. malayi mf burden com-
pared with vehicle control levels (0/4 mice mf negative; Fig. 2e). In comparison, seven day dosing with 15 mg/kg 
qd rifampicin mediated a near complete absence of viable mf from the peritoneum of infected mice (11/12 mice 
mf negative; P < 0.0001 vs vehicle; Fig. 2e). Seven-day doses of rifampicin exceeding 15 mg/kg qd mediated total 
absence of viable mf (35 mg/kg qd: 4/4 mice mf negative P < 0.05 vs vehicle, 25 mg/kg bid: 9/9 mice mf negative 
P < 0.001 vs vehicle; Fig. 2e).
Based on threshold effects of elevated dose rifampicin achieving >90% Wolbachia depletions from Brugia 
adult female tissues following seven day dosing, we tested efficacy against Onchocerca male worms in a novel 
SCID mouse model of onchocerciasis56 Rifampicin dosed at 35 mg/kg qd for seven or 14 days was compared with 
human bioequivalent doxycycline dosed for 28 days (a minimum clinical dose/duration determined to deplete 
>90% Wolbachia from adult O. volvulus tissues leading to macrofilaricidal activity50, (Fig. 2f). Male Onchocerca 
worm burdens were not affected by treatment compared with vehicle controls (Table 3). Bioequivalent doxycy-
cline mediated 99.6% median reduction in Wolbachia from male Onchocerca tissues following 28 days dosing 
(Fig. 2g). Seven-day dosing of rifampicin did not mediate any depletion in Wolbachia following washout period 
(0% median reduction) and was thus statistically inferior to doxycycline control (Kruskal-Wallis test P = 0.0013, 
Dunn’s multiple comparisons test, P < 0.001 vs DOX; Fig. 2g). In comparison, 14 day dosing of rifampicin medi-
ated 96.9% median reductions in Onchocerca Wolbachia, a level of efficacy that was statistically non-inferior to 
doxycycline dosed for 28 days (Fig. 2g).
PK-PD modelling. The empirical PK and pharmacological anti-Wolbachia efficacy measurements of dox-
ycycline and rifampicin were used to construct a PK-PD model (described in the methods section). An in vivo 
IC50 value was calculated based on the model for rifampicin (65.2 µg/ml), which was ~16-fold more potent than 
that calculated for doxycycline (1059 µg/ml; Table 1). IC50 values derived from the PK-PD model were 100,000 to 
Treatment 
Species
Vehicle 
B. malayi
DOX B. 
malayi RIF B. malayi
Vehicle O. 
ochengi
DOX O. 
ochengi
RIF O. 
ochengi
Dose (mg/kg) — 25 25 5 15 35 25 — 25 35 35
Doses/day — bid bid qd qd qd bid — bid qd qd
Duration (d) 28–42 28 42 7 7 7 7 28 28 7 14
SCID mouse (n) 25 5 4 4 12 4 9 6 3 3 3
Total worm (n) 248 27 67 73 34 78 100 19 13 5 7
Min 0 0 14 0 0 15 4 0 3 0 1
Median 9 6 24 23 2 20 7 3 4 0 1
Max 34 10 29 27 9 23 21 6 6 5 5
Female B. 
malayi (n) 159 17 49 54 22 51 50 — — — —
Min 0 0 11 11 0 0 0 — — — —
Median 6 4 15 12.5 1 16.5 5 — — — —
Max 23 7 23 18 6 18 12 — — — —
Wolbachia 
sample (n) 53 15 10 10 21 10 29 17 11 5 7
Table 3. Adult B. malayi or O. ochengi worm burden recoveries post-dosing.
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200,000 fold higher than those observed in vitro; however the ratio of calculated in vivo IC50 between rifampicin 
and doxycycline was aligned to the ratio empirically measured in vitro between the two drugs (~17-fold higher 
RIF vs DOX, Table 1).
Mouse – Human Bridging analysis. To compare rifampicin exposures observed in the SCID mouse model 
in comparison to those achieved in standard human clinical dose (600 mg), the overall exposure of rifampicin has 
been estimated in humans based on literature data (Fig. 3a). From this we determined the exposure in an average 
population of 70 kg humans after receiving 600 mg dose of rifampicin is significantly lower than the optimal expo-
sure in mice that results in >90% Wolbachia elimination in 7 days or less (this exposure is defined as the 24 hour 
steady state AUC of the 15 mg/kg rifampicin dose in mice which is 141.5 mg/hr/L). The human dose that would 
achieve this optimal mouse exposure was then determined via multiple Monte-Carlo simulations (3000 subjects 
per dose) at different doses from 5 mg/kg up to 45 mg/kg where the percentage of humans predicted to achieve 
the desired AUC at each dose has been recorded (Fig. 3b). The PK predictions of higher doses of Rifampicin agree 
with published results where the predicted Cmax and AUC were equivalent to observed PK in humans at elevated 
doses in clinical studies61. This would indicate that our dosing suggestion will achieve the desired exposure based 
on clinical PK data.
From those simulations, it is predicted that a minimum dose of 30–40 mg/kg is needed to achieve ‘curative’ 
exposure levels in human filariasis patients which also agrees with high dose RIF clinical studies61 that have 
shown a dose of 30 mg/kg or higher to achieve a steady-state AUC of 141.5 mg/hr/L in the vast majority of patients
Figure 3. Human-Mouse Bridging. PK profile of rifampicin in mouse at 15MKD (Black solid line) in 
comparison to exposures expected in man based on 600 mg dosing in 70 kg individuals (a) (green solid line 
representing median prediction and dashed red lines representing 5% and 95% percentiles of the prediction). 
% Probability of achieving optimal rifampicin exposure in humans at a dosing range of 4 mg/kg–45 mg/kg (b). 
(optimal exposure is defined as the median total 24 hour steady state AUC in mice receiving daily 15 mg/kg 
dose).
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Discussion
Targeting Wolbachia with antibiotics to deliver curative outcomes for filariasis is a promising drug develop-
ment strategy. The pharmacopeia of registered antibiotics present ‘low hanging fruit’ with the potential for rapid 
re-purposing62, 63. Further, the ‘slow kill’ effect post-Wolbachia depletion, manifest first on circulating or skin 
mf and then adult worms, avoids the problems of inflammatory adverse reactions which are associated with 
fast-killing direct filaricidal agents3, 33, 64–66. Indeed, this promotes anti-Wolbachia therapies as a safe drug devel-
opment strategy for to administer to L. loa co-endemic target populations67 who are at risk of severe neurological 
adverse reactions to rapid acting filaricides and thus provides a potential solution to problem areas of Central 
Africa toward an end game of onchocerciasis elimination68. Clinical trials with doxycycline have shown that 
depletion of Wolbachia from filarial nematodes can deliver significant macrofilaricidal activity when administered 
for 4 or more weeks38, 40–42, 51. However, the long period of administration and contraindications in children and 
pregnant women present logistical challenges to widespread scale-up in resource poor settings of Sub-Saharan 
Africa. Whilst we have recently identified minocycline as a superior anti-Wolbachia agent to doxycycline in the 
B. malayi SCID mouse model58 as part of the same tetracycline class, the same contraindications would apply. 
The ‘holy grail’ for an anti-Wolbachia macrofilaricide is thus demonstrable activity in administration times of a 
minimum of 2 weeks (ideally 1 week) and a safety profile for administration in loiasis co-infections, in children 
and in pregnant women34, 63.
We use here a validated screening system of in vitro cell assays and in vivo preclinical mouse models of filari-
asis56, 57 to test the efficacy of dose elevations of rifampicin and have identified a dose-dependent activity which 
has the potential to achieve Wolbachia depletions predictive of cure when administered for 1 week against the 
human lymphatic filaria B. malayi or 2 weeks against O. ochengi, the closest phylogenetic relative of O. volvulus.
We determine that rifampicin is >15 fold more potent than doxycycline in vivo. Rifampicin exhibited sig-
nificantly higher exposure per mg dose when compared to doxycycline. Also PK-PD modelling showed that 
rifampicin is more potent in reducing Wolbachia in vivo when exposure levels are matched to doxycycline. This 
superiority likely reflects the inherently higher (>16 fold) intrinsic potency of rifampicin against Wolbachia that 
is observed in vitro compared with doxycycline.
Corroborating rifampicin superiority versus doxycycline as an anti-Wolbachia agent, it has previously been 
reported, in mice experimentally infected with the rodent filaria, Litomosoides sigmodontis, that 25 mg/kg bid 
dosages of rifampicin result in a more profound decrease in Wolbachia levels in adult worms when compared to 
a similar dose of doxycycline48. Also, in a pilot study using the related, registered rifamycin, rifapentine, >90% 
depletion of Wolbachia was measured in O. ochengi males implanted into SCID mice, following two weeks 25 mg/
kg bid dosing56. However, clinical studies in humans have shown that rifampicin administered for two or four 
weeks has inferior activity to six-week doxycycline in onchocerciasis69, 70 and neither is combining rifampicin and 
doxycycline for two weeks sufficient to achieve significant macrofilaricidal activity54.
Our PK-PD model offers a rational explanation for the discrepancy in the activity of rifampicin in mice and 
humans, where doxycycline activity is similar across mouse model and human clinical studies, yet rifampicin 
seems to be dramatically more active in the mouse than in humans. We identify effective dosages in the mouse 
exceed the exposure of rifampicin achieved in humans when the drug is administered at ‘standard dose’ (~10 mg/
kg qd or 600 mg). Indeed, exploring dose ranges more in line with standard human dose exposures, (5 mg/kg qd) 
rifampicin in the mouse is insufficient to achieve >90% Wolbachia depletion in 1 week against B. malayi.
The currently established 600 mg dose of rifampicin has not been predicated on PK-PD analysis but rather has 
been chosen based on drug cost, due to rifampicin semi-synthetic production in the 1970 s when the dosage was 
established71. However, recently the cost of rifampicin production has dramatically decreased and dose escalation 
studies have been initiated for TB patients. Higher doses of rifampicin (up to 35 mg/kg) have recently been proven 
to be safe in a clinical study61. The same study undertook human PK analysis and has shown that rifampicin expo-
sure increases as the dose is increased. From this data we predict that the target exposure level required to deplete 
>90% Wolbachia from target filarial species in 1–2 weeks to ultimately deliver short-course curative efficacy 
against filariasis is achievable in humans when a dose of 30–35 mg/kg is administered. Importantly, clinical data 
supports that for doses of up to 35 mg/kg, given for periods over 2 weeks, no serious side effects are observed and 
that grade 1 and grade 2 side effects are randomly distributed across low and higher doses indicating no increased 
risk of side effects with elevated doses of rifampicin. A recent additional study where a dose of 35 mg/kg of RIF 
was administered to TB patients has also reported similar conclusions in relation to safety72.
Because elevated rifampicin dosages for filariasis cure are predicted in a 1–2 week dose exposure time frame, 
this is unlikely to result in resistant strains of M tuberculosis (TB), as there is no evidence for rifampicin resistance 
occurrence when administered for short periods of time73, 74.
Rifampicin has a number of drug-drug interactions of clinical significance that have been previously 
reported75. Those interactions can result in the reduction of exposure of other drugs that are taken concomitantly 
with Rifampicin, and doses might need to be altered, especially for patients who are on HIV medication.
Conclusions
Using PK-PD modelling of drug activity in preclinical filarial mouse models, we show that a clinically safe dose 
of rifampicin can be administered for 1–2 week short courses to elicit >90% reductions in Wolbachia, predic-
tive of the macrofilaricidal activity observed when Wolbachia is targeted by doxycycline, administered for 4–6 
weeks. This treatment regimen would be compatible for use in children and during pregnancy and, because of 
the shortened duration of administration required, would be more readily deliverable by health care systems in 
resource-poor community settings. A 35 mg/kg dose has been proven as safe over a period of 2 weeks, and it has 
previously been shown that such short durations of treatment will not produce resistant strains of M. tuberculosis. 
We recommend that both a 35 mg/kg 1 and 2 week dose of rifampicin be urgently examined in lymphatic filariasis 
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and onchocerciasis randomised controlled clinical trials to test whether such short-course treatment regimens are 
indeed sufficient to elicit equivalent curative activities to long course doxycycline.
Methods
Mice. Six to ten week old male BALB/c SCID (Harlan Laboratories, UK) or male CB.17 BALB/c SCID mice 
(Charles River, UK) were used for experiments. Mice were kept at the Biomedical Services Unit (BSU) at the 
University of Liverpool, UK, in specific pathogen-free (SPF) conditions or at The Research Foundation for 
Tropical Medicine and The Environment, Buea, Cameroon, in individually-ventilated caging. All experiments on 
animals were approved by The Animal Welfare and Ethical Review Board, Liverpool School of Tropical Medicine, 
UK, or the University of Buea Animal Ethics Review Board, Cameroon. Studies were conducted in accordance 
with Home Office legislation (UK) and matching welfare standards were applied in Cameroon.
In vitro potency studies. The anti-Wolbachia potency of doxycycline and rifampicin for use in the PK-PD 
model was determined in vitro, utilising the routine A·WOL screening assay as described previously57. In brief the 
mosquito (Aedes albopictus) derived cell line C6/36 (ATCC number CRL-1660), stably infected with Wolbachia 
pipientis (wAlbB) (C6/36 wAlbB) was incubated with the relevant drugs in a concentration range in order to 
determine a dose response. The drugs were incubated for 7 days with 2,000 cells per well on a 384 well plate 
(CellCarrier-384 Ultra, PerkinElmer) in Leibovitz media (Life Technologies™) supplemented with 20% foetal 
bovine serum (FBS, Fisher Scientific), 2% tryptose phosphate broth (Sigma-Aldrich) and 1% non-essential amino 
acids (Sigma-Aldrich). The end-point read out utilised DNA staining of both the host cell nuclei and intracellular 
Wolbachia (SYTO® 11) combined with a high content imaging system (Operetta®, PerkinElmer) and analysed 
using the associated Harmony® software through a cytoplasm texture analysis.
Brugia malayi experimental infections. The Brugia malayi lifecycle was maintained through mosquitoes 
and susceptible Meriones gerbils at LSTM. To generate infective B. malayi larvae for infections, female adult Aedes 
aegypti mosquitoes were fed with microfilariae collected from infected gerbils by catheterisation, as described 
previously76, that were mixed with human blood. Mosquitoes were fed through an artificial membrane feeder 
(Hemotek®). Blood-fed mosquitoes were reared for 14 days to allow for development to the L3 stage. L3 were 
then collected from infected mosquitoes by crushing and concentrated using a Baermann’s apparatus and RPMI 
medium. 100 motile L3 were collected and then injected into mice via the intra-peritoneal route. Efficiency of 
inoculations was confirmed by needle washout.
Onchocerca ochengi surgical implantations. Viable male Onchocerca ochengi were aseptically isolated 
from naturally parasitized cattle as described previously56. Between 10–11 male Onchocerca were surgically 
implanted into the peritoneal cavity of CB.17(BALB/c) SCID mice under anaesthesia as described previously56.
Drug treatments. Six weeks after B. malayi experimental infection or 3 days post O. ochengi surgical implan-
tation, SCID mice received 100 µL compound via oral gavage at variable doses and for variable treatment lengths 
as described and indicated in further detail in the main text. The drug doses and routes used were: Doxycycline 
(25 mg/kg qd or bid po and rifampicin (1.25 mg/kg–25 mg/kg qd or bid po). Doxycycline was dissolved in water, 
while rifampicin was dissolved in 55% polyethylene glycol 300; 25% propylene glycol; 20% water. All drugs and 
vehicle reagents were purchased from Sigma Aldrich.
Parasitological readouts. Seven or twelve weeks after B. malayi experimental infection or 38 days after 
O. ochengi surgical implantation, mice were necropsied. Adult filariae and released B. malayi mf were recovered 
by a combination of peritoneal washings using wash media (RPMI containing P/S) and subsequent dissection 
of abdominal cavities. To quantify B. malayi mf, samples were centrifuged at 1200 rpm for 5 min. Excess super-
natants were removed and the remaining volume quantified. Three 20 µL volumes were then enumerated for mf 
by microscopy, scoring as motile or stretched immotile. Adult filariae were observed for motility, washed in cold 
PBS and parasite stages enumerated. A minimum of ten B. malayi females and five O. ochengi males per treatment 
group of 3–5 mice were collected into individual Eppendorf tubes to be processed for qPCR.
DNA extraction and PCR quantification of Wolbachia. DNA was extracted from worm samples using 
a DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer’s instructions. Levels of Bm Wolbachia sur-
face protein (wsp) gene copy numbers were quantified using qPCR as previously described77. Levels of Onchocerca 
Wolbachia wsp and filarial gst gene copy numbers were similarly quantified as previously described56.
PK Studies. To establish the pharmacokinetic profiles of rifampicin and doxycycline, rich pharmacoki-
netic studies were performed in uninfected male SCID mice (weight 24–28 g). Doxycycline (25 mg/kg bid) or 
rifampicin (5 mg/kg qd or 25 mg/kg bid) were administered orally for up to seven days. For all PK studies, a total 
of 11 samples were collected at discrete time points between 0 and 24 hour post dose at days 1 and 7). Serial blood 
samples were collected at days 1 and 7 of dosing via the tail vein where a microincision was performed and 20 µL 
of blood collected using a pipette with a pre-heparinised tip. Blood samples were directly lysed with 40 µL of ice 
cold ddH2O and then frozen at −80 °C until time of bioanalysis.
Bioanalysis. Rifampicin concentrations were determined by LCMS (liquid chromatography mass spectrom-
etry) using an appropriate internal standard and were validated to internationally recognised acceptance criteria 
[FDA-guidelines]. Chromatographic separation was achieved using a gradient programme. The UHPLC (ultra-
high pressure liquid chromatography) system was interfaced with a triple-quadruple TSQ Quantum Access mass 
spectrometer (Thermo Scientific, Hemel Hempstead, UK) with a heated-electrospray ionization (H-ESI) source. 
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An E2M28 rotary vacuum pump (Edwards High Vacuum International, West Sussex, UK), an NM30LA nitrogen 
generator (Peak Scientific, Renfrewshire, UK) and 99% pure argon gas (10 L, BIP10, Air Products, Liverpool, 
UK) were used. Blood samples (20 μl) containing rifampicin were extracted with a mixture of acetonitrile and 
methanol (80:20 v/v). The subsequent mix was then filtered through 96 well filter plate (Millipore, UK). The 
resultant filtrate was then transferred to a 96 deep well plate containing 40 µl of (10 mg/ml) ascorbic acid, 10 µl of 
this resultant mixture was then injected into the LC-MS/MS. The assay was linear in the range 10–10,000 ng/ml 
for rifampicin.
PK-PD Modelling. A PK-PD model as described in equations 1 and 2 has been developed and used to fit 
parasitological read-outs from experiments in infected mice. The pharmacological output for all PK/PD analyses 
was Wolbachia counts as estimated in qPCR experiments in the quantitation of wsp DNA levels. Pmetrics® 78 was 
used in modelling PK/PD data in all experiments. The following differential equations were used:
For the PK component:
=
⋅ ⋅
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Where Cp is the drug concentration in blood at any given time, F is the fraction available for oral absorption, ka 
is the rate of absorption from gut to blood, V is the volume of distribution and kel is the rate of elimination from 
the systemic circulation.
For the PD component, a relationship was built to describe the effect of the drug upon Wolbachia levels using 
a dynamic Emax model:
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X1 is the observed Wolbachia levels as estimated by qPCR, kgrowth is the rate of bacterial growth which was set at 
0 due to the absence of any evidence of bacterial growth beyond the time of treatment and no evidence of recru-
descence within the time frame of the experiment. Kkill is the maximum possible rate of kill of bacteria and has 
been fixed to the in vitro kill rate that could be achieved at the maximum concentration of drug. IC50 is the blood 
concentration required to achieve 50% of the maximal kill rate of Wolbachia in the adult worm in the mouse.
Statistics. PK parameters between doxycycline and rifampicin were compared by Mann-Whitney test. 
Percentage Wolbachia reductions in filariae following in vivo treatments were calculated from median vehicle con-
trol levels derived from the same experimental infection and screen. Where repeat experiment data (Wolbachia 
loads normalised to control, worm enumerations or viable mf enumerations per mouse) were available, data was 
pooled. Grouped continuous variables were tested for normal distribution by D’Agostino & Pearson omnibus 
normality tests. Continuous variables failing normal distribution tests were Log10 transformed and re-tested. 
Continuous variables satisfying the assumptions of normal distribution were examined by 1 way ANOVA 
with Dunnett’s multiple tests post-hoc. Variables not satisfying the assumption of normality were compared by 
Kruskal-Wallis Test with Dunn’s Multiple Tests, post-hoc. Significance levels are indicated P < 0.05*, P < 0.01** 
P < 0.001*** P < 0.0001****. All statistics were undertaken using GraphPad Prism v6 software.
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